| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 241,2 M € | +13.0% | 213,4 M € | +13.8% | 187,5 M € | +20.1% | 156,1 M € | +7.8% | 144,8 M € | -2.0% | 147,7 M € | -10.5% | 165,0 M € | -5.7% | 175,1 M € | +3.0% | 169,9 M € | +6.9% | 159,0 M € | -4.8% | 166,9 M € | -16.6% | 200,2 M € | -7.4% | 216,3 M € | -3.9% | 225,2 M € | -6.3% | 240,2 M € | -8.2% | 261,8 M € | -11.7% | 296,3 M € | -3.2% | 306,2 M € | |
| EBITDA | 8,6 M € | +29.4% | 6,7 M € | +15.5% | 5,8 M € | +57.2% | 3,7 M € | -29.7% | 5,2 M € | +1.9% | 5,1 M € | -15.9% | 6,1 M € | -24.8% | 8,1 M € | -12.1% | 9,2 M € | +238.8% | 2,7 M € | -73.0% | 10,1 M € | -18.1% | 12,3 M € | -0.3% | 12,3 M € | +31.0% | 9,4 M € | -44.4% | 16,9 M € | -35.3% | 26,2 M € | +29.4% | 20,2 M € | -39.1% | 33,2 M € | |
| Operating profit | 8,9 M € | +33.2% | 6,7 M € | +11.7% | 6,0 M € | +68.3% | 3,6 M € | -20.1% | 4,4 M € | +4.2% | 4,3 M € | -18.4% | 5,2 M € | -27.6% | 7,2 M € | -13.5% | 8,4 M € | +355.2% | 1,8 M € | -79.8% | 9,1 M € | -19.3% | 11,2 M € | +1.6% | 11,1 M € | +15.3% | 9,6 M € | -36.5% | 15,1 M € | -40.4% | 25,3 M € | +32.1% | 19,2 M € | -40.1% | 32,0 M € | |
| Profit/loss | 7,0 M € | +33.0% | 5,3 M € | +27.9% | 4,1 M € | +70.5% | 2,4 M € | -19.3% | 3,0 M € | -1.4% | 3,0 M € | -17.0% | 3,7 M € | +9.8% | 3,3 M € | -34.4% | 5,1 M € | +273.8% | 1,4 M € | -69.0% | 4,4 M € | -49.9% | 8,8 M € | +5.9% | 8,3 M € | +7.5% | 7,7 M € | -11.6% | 8,7 M € | -51.4% | 17,9 M € | +33.0% | 13,5 M € | -44.5% | 24,3 M € | |
| Equity | 4,8 M € | -57.5% | 11,2 M € | -55.6% | 25,4 M € | +19.5% | 21,2 M € | -2.7% | 21,8 M € | +16.0% | 18,8 M € | +19.3% | 15,8 M € | +30.4% | 12,1 M € | -18.0% | 14,7 M € | -67.0% | 44,6 M € | -77.3% | 196,3 M € | +2.3% | 191,9 M € | +4.8% | 183,1 M € | +4.7% | 174,8 M € | +4.6% | 167,1 M € | +5.5% | 158,4 M € | +12.8% | 140,4 M € | +10.6% | 126,9 M € | |
| Total assets | 58,2 M € | -3.9% | 60,5 M € | +0.8% | 60,1 M € | +24.5% | 48,3 M € | -2.0% | 49,2 M € | +16.9% | 42,1 M € | -33.5% | 63,3 M € | +1.4% | 62,4 M € | +19.7% | 52,1 M € | -38.3% | 84,5 M € | -62.5% | 225,2 M € | -7.1% | 242,5 M € | +2.1% | 237,4 M € | -0.5% | 238,5 M € | +4.1% | 229,2 M € | +12.7% | 203,4 M € | -0.7% | 204,9 M € | +4.3% | 196,4 M € | |
| Cash | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 9,4 k € | -99.8% | 4,2 M € | — | |||||||||||||||||
| Debts | 41,7 M € | +10.4% | 37,7 M € | +70.5% | 22,1 M € | +12.2% | 19,7 M € | -7.1% | 21,2 M € | +18.9% | 17,9 M € | -56.4% | 41,0 M € | -10.6% | 45,9 M € | +46.1% | 31,4 M € | -2.1% | 32,1 M € | +47.0% | 21,8 M € | -51.5% | 45,0 M € | -3.9% | 46,8 M € | -5.2% | 49,4 M € | -9.1% | 54,3 M € | +58.3% | 34,3 M € | -29.9% | 49,0 M € | -22.3% | 63,0 M € | |
| Staff | 194,7 | 194,3 | 192,9 | 189,2 | 193,3 | 178,8 | 176,2 | 189,6 | 195,8 | 188,2 | 197,9 | 227,8 | 248,1 | 279 | 310,5 | 328,6 | 359,9 | 405,4 | ||||||||||||||||||
Public limited company · Wavre · incorporated on 01/01/1968 · 194,7 ETP
Public limited company profitable and well capitalised. Cash position declining (-99.8%).
Solid counterparty for a standard engagement.
GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline is a Public limited company incorporated in 1968. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Wavre. It employs on average 194,7 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette